Brought to you by 
Paladin Labs buys ViRexx Medical
Jan 2009
Executive Summary
Canadian specialty pharmaco Paladin Labs has acquired all of the outstanding shares of ViRexx Medical (developing therapeutics for infectious diseases and cancer) for $1.25mm up front plus another $2.5mm in potential earn-outs.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Full Acquisition
- Includes Earnout
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Paladin Labs buys ViRexx Medical
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice